Long COVID Burden: 65 Million Affected, Healthcare Systems Unprepared
Objective
Quantify the global burden of Long COVID, assess healthcare system capacity gaps, and identify the mechanisms driving persistent symptoms.
Methodology
Systematic review of Long COVID cohort studies (n>1000) from 30 countries 2021-2026, combined with WHO and CDC surveillance data. Economic burden estimated using human capital approach with ILO productivity loss data.
Findings
65 million people globally experience persistent Long COVID symptoms (WHO 2025). 23% of infected individuals develop post-acute sequelae lasting >12 weeks. Healthcare utilisation increases 3.5x for Long COVID patients vs matched controls. Annual economic cost estimated at $3.7T globally. Healthcare systems have not adapted — most countries lack Long COVID clinics, diagnostic pathways, or disability recognition frameworks.
Key Assumptions
- •Long COVID symptom persistence rates based on pre-Omicron variants may overstate current burden.
Limitations
- •Heterogeneity in Long COVID definitions across studies makes precise global estimates uncertain.
Share
Evaluation Scores
Data Sources
WHO Global Long COVID Surveillance Report 2025
government
Reliability: 93%
Lancet Long COVID Commission 2025
academic
Reliability: 92%
ILO Productivity Loss from Post-Acute Conditions 2024
government
Reliability: 88%